Adalimumab dose escalation is effective for managing secondary loss of response in Crohn's disease
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Adalimumab dose escalation is effective for managing secondary loss of response in Crohn's disease
Authors
Keywords
-
Journal
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
Volume 40, Issue 9, Pages 1044-1055
Publisher
Wiley
Online
2014-09-03
DOI
10.1111/apt.12940
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Efficacy and Safety of Adalimumab in Canadian Patients with Moderate to Severe Crohn’s Disease: Results of the Adalimumab in Canadian SubjeCts with ModErate to Severe Crohn’s DiseaSe (ACCESS) Trial
- (2016) Remo Panaccione et al. CANADIAN JOURNAL OF GASTROENTEROLOGY
- Development of an Algorithm Incorporating Pharmacokinetics of Adalimumab in Inflammatory Bowel Diseases
- (2014) Xavier Roblin et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Su1396 Crohn's Disease Outpatients Treated With Adalimumab Have an Earlier Loss of Response and Requirement for Dose Intensification Compared to Infliximab
- (2014) Christopher Ma et al. GASTROENTEROLOGY
- Crohn's disease outpatients treated with adalimumab have an earlier secondary loss of response and requirement for dose escalation compared to infliximab: A real life cohort study
- (2014) Christopher Ma et al. Journal of Crohns & Colitis
- Temporary adalimumab dose escalation is effective in Crohn's disease patients with secondary non-response
- (2013) K. Sutharshan et al. Journal of Crohns & Colitis
- Clinical utility of newly developed immunoassays for serum concentrations of adalimumab and anti-adalimumab antibodies in patients with Crohn’s disease
- (2013) Hirotsugu Imaeda et al. JOURNAL OF GASTROENTEROLOGY
- Adalimumab dose escalation and dose de-escalation success rate and predictors in a large national cohort of Crohn's patients
- (2012) Filip Baert et al. Journal of Crohns & Colitis
- Predictors of dose escalation of adalimumab in a prospective cohort of Crohn’s disease patients
- (2011) E. Bultman et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Loss of Response and Need for Adalimumab Dose Intensification in Crohn's Disease: A Systematic Review
- (2011) Vincent Billioud et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Adalimumab produces clinical remission and reduces extraintestinal manifestations in Crohnʼs disease: Results from CARE
- (2011) Robert Löfberg et al. INFLAMMATORY BOWEL DISEASES
- The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD With the European Crohn's and Colitis Organization: When to Start, When to Stop, Which Drug to Choose and How to Predict Response?
- (2010) Geert R D'Haens et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Clinical Experience with Adalimumab in a Multicenter Swiss Cohort of Patients with Crohn’s Disease
- (2010) Cristina Nichita et al. DIGESTION
- Adalimumab for Crohnʼs disease in clinical practice at Mayo clinic: The first 118 patients
- (2010) Jason M. Swoger et al. INFLAMMATORY BOWEL DISEASES
- Dosage adjustment during long-term adalimumab treatment for Crohnʼs disease: Clinical efficacy and pharmacoeconomics
- (2010) William J. Sandborn et al. INFLAMMATORY BOWEL DISEASES
- Systematic review: the short-term and long-term efficacy of adalimumab following discontinuation of infliximab
- (2009) C. MA et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Prospective Evaluation of Anti-Tumor Necrosis Factor Therapy Guided by Magnetic Resonance Imaging for Crohn's Perineal Fistulas
- (2009) Siew C Ng et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Influence of Trough Serum Levels and Immunogenicity on Long-term Outcome of Adalimumab Therapy in Crohn's Disease
- (2009) Konstantinos Karmiris et al. GASTROENTEROLOGY
- Immunogenicity negatively influences the outcome of adalimumab treatment in Crohn’s disease
- (2008) R. L. WEST et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Early clinical experience with adalimumab in treatment of inflammatory bowel disease with infliximab-treated and naïve patients
- (2008) A. SWAMINATH et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Adalimumab for Crohn’s disease with intolerance or lost response to infliximab: a 3-year single-centre experience
- (2008) A. OUSSALAH et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort
- (2008) F Schnitzler et al. GUT
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More